Clinical Study of Seldiflexe (Sildenafil 12.5 mg Oral Gel Sachet in Yemeni Honey) in Patients with Erectile Dysfunction

Introduction: Erectile dysfunction (ED) is a prevalent disorder affecting millions of men worldwide, with significant implications on quality of life and psychological well-being. The aim of this study was to evaluate the efficacy, safety, and tolerability of Seldiflexe, a novel oral gel sachet formulation of sildenafil citrate (12.5 mg in 5 g Yemeni honey), in comparison with standard sildenafil tablets (25 mg). Methods: A randomized, double-blind, controlled trial was conducted on 80 male patients diagnosed with erectile dysfunction (ED). Patients were allocated to two groups: Seldiflexe sachet (n=40) or standard sildenafil tablet (n=40) for 4 weeks. Primary endpoints included improvement in the International Index of Erectile Function (IIEF) scores, onset of action, and adverse event profile. Results: demonstrated that Seldiflexe produced a significantly faster onset of action (mean 30 ± 5 min vs 50 ± 8 min, p<0.01) and improved tolerability, while maintaining comparable efficacy to standard tablets. This study suggests that Seldiflexe is a safe, effective, and patient-friendly alternative for the treatment of ED. Conclusion: Seldiflexe (sildenafil 12.5 mg in Yemeni honey oral gel sachet) is a safe, effective, and well-tolerated alternative to conventional sildenafil 12.5 mg tablets for ED treatment. Its faster onset and better patient acceptability make it a promising innovation in sexual medicine. Key words: Seldiflexe, Yemeni, Honey, Oral, Gel, Seldinafil